Entrectinib

TargetMol
Product Code: TAR-T3678
Supplier: TargetMol
CodeSizePrice
TAR-T3678-2mg2mg£99.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3678-5mg5mg£114.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3678-1mL1 mL * 10 mM (in DMSO)£121.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3678-10mg10mg£136.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3678-25mg25mg£161.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3678-50mg50mg£208.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3678-100mg100mg£309.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Entrectinib is an inhibitor of TrkA (IC50: 1.7 nM), TrkB (IC50: 0.1 nM), and TrkC (IC50: 0.1 nM), as well as anaplastic lymphoma kinase (ALK; IC50: 1.6 nM) and C-ros oncogene 1 (ROS1; IC50: 0.2 nM). Entrectinib blocks proliferation of ALK-dependent cell lines, including those with C1156Y or L1196M resistance mutations, and inhibits ALK?dependent signaling. It has been shown to inhibit the growth of a non-small cell lung Y cell line bearing an EML4-ALK rearrangement. In mice bearing various ROS1, Trk, or ALK-driven xenografts, Entrectinib has been shown to induce tumor regression.
CAS:
1108743-60-7
Formula:
C31H34F2N6O2
Molecular Weight:
560.65
Pathway:
Tyrosine Kinase/Adaptors; Angiogenesis; Immunology/Inflammation; Autophagy
Purity:
0.9961
SMILES:
CN1CCN(CC1)c1ccc(C(=O)Nc2n[nH]c3ccc(Cc4cc(F)cc(F)c4)cc23)c(NC2CCOCC2)c1
Target:
Trk receptor; ROS; ALK; Autophagy; ROS Kinase

References

Ardini E, et al. Mol Cancer Ther. 2009, 8, A244. Rolfo C, et al. Expert Opin Investig Drugs. 2015, 24(11), 1493-1500. Lyer R, et al. Cancer Res. 2015, 75, 5390. Shi S, Ma B, Sun F, et al. Zafirlukast inhibits the growth of lung adenocarcinoma via inhibiting TMEM16A channel activity. Journal of Biological Chemistry. 2022, 298(3). Qin Q, Fu Q, Wang X, et al.Design, synthesis and biological evaluation of novel indolin-2-one derivatives as potent second-generation TRKs inhibitors.European Journal of Medicinal Chemistry.2023: 115291.